ERAS Key Statistics, Chart & Performance
The current stock price of ERAS is 9.75 USD. In the past month the price increased by 180.18%. In the past year, price increased by 408.47%.
ERAS Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ERAS. When comparing the yearly performance of all stocks, ERAS is one of the better performing stocks in the market, outperforming 99.52% of all stocks.
ERAS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ERAS. While ERAS has a great health rating, there are worries on its profitability.
ERAS Financial Highlights
Over the last trailing twelve months ERAS reported a non-GAAP Earnings per Share(EPS) of -0.45. The EPS increased by 45.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.37% | ||
| ROE | -36.7% | ||
| Debt/Equity | 0 |
ERAS Forecast & Estimates
15 analysts have analysed ERAS and the average price target is 6.53 USD. This implies a price decrease of -33.05% is expected in the next year compared to the current price of 9.75.
ERAS Ownership
ERAS Latest News, Press Relases and Analysis
About ERAS
Company Profile
Erasca, Inc. is a clinical stage precision oncology company. The company is headquartered in San Diego, California and currently employs 103 full-time employees. The company went IPO on 2021-07-15. The firm is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The firm has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Company Info
ERASCA INC
3115 Merryfield Row, Third Floor
San Diego CALIFORNIA US
Employees: 103
Phone: 18584656511
ERASCA INC / ERAS FAQ
Can you describe the business of ERASCA INC?
Erasca, Inc. is a clinical stage precision oncology company. The company is headquartered in San Diego, California and currently employs 103 full-time employees. The company went IPO on 2021-07-15. The firm is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The firm has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
What is the stock price of ERASCA INC today?
The current stock price of ERAS is 9.75 USD. The price increased by 1.46% in the last trading session.
Does ERAS stock pay dividends?
ERAS does not pay a dividend.
What is the ChartMill technical and fundamental rating of ERAS stock?
ERAS has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of ERASCA INC (ERAS) based on its PE ratio?
ERASCA INC (ERAS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.45).
Can you provide the market cap for ERASCA INC?
ERASCA INC (ERAS) has a market capitalization of 2.77B USD. This makes ERAS a Mid Cap stock.
Can you provide the short interest for ERAS stock?
The outstanding short interest for ERASCA INC (ERAS) is 8.99% of its float.